ChIP-seq analysis of H3K27ac changes in pancreatic cancer cells treated with EZH2 and KRAS inhibitors
Our study demonstrates that combined treatment with the EZH2 inhibitor tazemetostat and the KRAS inhibitor RMC-6236 markedly activates the expression of senescence-associated secretory phenotype (SASP) genes in pancreatic cancer, thereby enhancing the therapeutic efficacy of RMC-6236 and potentially providing a strategy to overcome resistance to KRAS inhibition. To characterize the epigenetic features underlying SASP gene activation, H3K27ac ChIP-seq was performed in PSN1 cells treated with DMSO, tazemetostat, RMC-6236, or the combination of both inhibitors. Overall design: ChIP-seq analysis of H3K27ac in PSN-1 cells treated with DMSO, tazemetostat, RMC-6236, or their combination.